Evidence map›Paper›PMID 31547467›Full record

ArticleDiagnostics (Basel, Switzerland)2019

Analytical Evaluation of an NGS Testing Method for Routine Molecular Diagnostics on Melanoma Formalin-Fixed, Paraffin-Embedded Tumor-Derived DNA.

Irene Mancini, Lisa Simi, Francesca Salvianti, Francesca Castiglione, Gemma Sonnati, Pamela Pinzani

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostics (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Melanoma genomics - will we go beyond BRAF in clinics?Journal of cancer research and clinical oncology · 2024
    Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Irene ManciniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy. irene.mancini@unifi.it.ORCID 0000-0002-7814-6435
Lisa SimiMolecular and Clinical Biochemistry Laboratory, Careggi University Hospital, 50139 Florence, Italy. lisa.simi@unifi.it.
Francesca SalviantiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy. francesca.salvianti@unifi.it.ORCID 0000-0003-3235-4033
Francesca CastiglioneHistopathology and Molecular Diagnostics, Careggi University Hospital, 50139 Florence, Italy. francesca.castiglione@gmail.com.
Gemma SonnatiDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy. sonnatigemma@gmail.com.
Pamela PinzaniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50139 Florence, Italy. pamela.pinzani@unifi.it.ORCID 0000-0003-4017-3574

Funding

Regione Toscana BIO16028
6 · The paper itself

Abstract

Next Generation Sequencing (NGS) is a promising tool for the improvement of tumor molecular profiling in view of the identification of a personalized treatment in oncologic patients. To verify the potentiality of a targeted NGS (Ion AmpliSeq™ Cancer Hotspot Panel v2), selected melanoma samples (

Indexed as

BRAF V-raf murine sarcoma viral oncogene homolog Bmelanomanext generation sequencingsequenom MassARRAY systemsomatic mutation

Identifiers

PMID31547467
PMCPMC6787639

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.